Prolonged survival of pancreatic islet allografts implanted in diabetic BB rats was achieved by encapsulation of individual islets in a protective biocompatible alginate-polylysine-alginate membrane without immunosuppression. Intraperitoneal transplantation of the encapsulated islets reversed the diabetic state of the recipients within 3 days and maintained normoglycemia for 190 days. Normal body weight and urine volume were maintained during this period, and no cataracts were detected in the transplant recipients. In contrast, control rats receiving transplants of unencapsulated islets experienced normoglycemia for <2 wk. These results demonstrated that microencapsulation can protect allografted islets from both graft rejection and autoimmune destruction without immunosuppression in an animal model that mimics human insulindependent diabetes. Diabetes 39:519-22,1990 P ancreatic islet transplantation has emerged as one of the fastest-growing areas of investigation into an improved treatment for type I (insulin-dependent) diabetes. Islet transplants have been shown to prevent complications associated with diabetes in experimental animals (1). However, with the growing evidence that type I diabetes is an autoimmune disease, graft rejection and the autoimmune destruction of transplanted cells have remained major problems. One of the possible solutions that has been developed in recent years is the encapsulation of donor islets in a protective biocompatible alginate-polylysine-alginate membrane. Transplants of encapsulated islets have been successful in protecting both allo-and xenografts from reFrom the University of Toronto, Department of Physiology, Toronto, Ontario, Canada.
Prolonged survival of pancreatic islet allografts implanted in diabetic BB rats was achieved by encapsulation of individual islets in a protective biocompatible alginate-polylysine-alginate membrane without immunosuppression. Intraperitoneal transplantation of the encapsulated islets reversed the diabetic state of the recipients within 3 days and maintained normoglycemia for 190 days. Normal body weight and urine volume were maintained during this period, and no cataracts were detected in the transplant recipients. In contrast, control rats receiving transplants of unencapsulated islets experienced normoglycemia for <2 wk. These results demonstrated that microencapsulation can protect allografted islets from both graft rejection and autoimmune destruction without immunosuppression in an animal model that mimics human insulindependent diabetes. Diabetes 39:519-22,1990 P ancreatic islet transplantation has emerged as one of the fastest-growing areas of investigation into an improved treatment for type I (insulin-dependent) diabetes. Islet transplants have been shown to prevent complications associated with diabetes in experimental animals (1) . However, with the growing evidence that type I diabetes is an autoimmune disease, graft rejection and the autoimmune destruction of transplanted cells have remained major problems. One of the possible solutions that has been developed in recent years is the encapsulation of donor islets in a protective biocompatible alginate-polylysine-alginate membrane. Transplants of encapsulated islets have been successful in protecting both allo-and xenografts from re-jection and also in reversing streptozocin-induced diabetes in rats and mice (2, 3) . Our study determined the effectiveness of the immunoisolation environment provided by the membrane in an animal model (BB rat) with an autoimmune etiology similar to that of human type I diabetes (4, 5) .
RESEARCH DESIGN AND METHODS
Pancreatic islets were isolated from male Wistar rats (Charles River Canada, Montreal) weighing 300-350 g. BB rats (University of Massachusetts Medical School, Worcester) weighing 207-310 g were used as transplant recipients. Only rats with high persisting fasting glucose levels were used as transplant recipients. Fasting plasma glucose concentrations in the BB rats were monitored weekly with blood samples obtained from the orbital sinus and analyzed with the Beckman Glucose Analyzer 2 system. Islets were isolated from donor rat pancreases by a modified collagenase (type V, Sigma, St. Louis, MO)-digestion technique (6) and hand picked with the aid of a dissecting microscope. The isolated islets were cultured for 1 day in CMRL-1640 medium supplemented with 7.5% (vol/vol) calf serum, 5.5 mM glucose, and antibiotics in a humidified atmosphere of 5% CO 2 /95% air at 37°C before microencapsulation.
The microencapsulation method used in this study was a modification of the method of Sun and O'Shea (1). Isolated pancreatic rat islets were suspended in 1.5% (wt/vol) sodium alginate (Kelco Gel LV, San Diego, CA) at a concentration of 1-2 x 10 3 islets/ml. Spherical droplets were formed by syringe-pump extrusion or electrostatic droplet generator and collected in a 1.1% CaCI 2 solution. Subsequently, the gelled droplets were washed with 0.9% saline solution before suspension in 0.15% poly-L-lysine (16,000-22,000 M,, Sigma) for 10 min. The droplets were suspended in 0.15% sodium alginate for 4 min. The capsules were then allowed to react in 55 mM sodium citrate solution for 6 min and finally washed with saline solution and culture medium before incubation in a humidified atmosphere at 37°C. Each capsule contained one or two islets and had a diameter ranging from 0.5 to 0.7 mm.
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For scanning electron microscopy, ruptured capsules were fixed in 2% glutaraldehyde, dried in a critical-point dryer, and mounted on an alumium stud. A coat of gold was applied, and the specimen was studied under a scanning electron microscope.
A group of 20 free islets and a group of 20 microencapsulated islets were incubated in 2 ml culture medium as described above for two consecutive 24-h periods after which samples were obtained. During the first 24-h period, the islets were exposed to a glucose concentration of 2.7 mM. The culture fluid was then replaced with fresh medium containing 20 mM glucose, and 24-h samples were again collected. The samples were then assayed for insulin with the Count-a-Count radioimmunoassay kit (Diagnostic Products, Los Angeles, CA).
A total of 15 diabetic BB rats received intraperitoneal transplants of either free or microencapsulated islets suspended in saline solution under light Metofane anesthesia. In the experimental group of 10 diabetic rats, 8 received a single transplant of 4-5 x 10 3 microencapsulated islets, whereas 2 were given a second transplant. In the control group of 5 diabetic rats, all received a single transplant of an equal number of unencapsulated islets.
RESULTS
Scanning electron microscopy showed that the ruptured capsule in Fig. 1 contained an intact islet, indicating the islet had not been damaged during the encapsulation process. Insulin secretion from encapsulated islets was comparable to insulin secretion by unencapsulated islets in a 24-h culture study. Insulin secretion under low-glucose stimulation (2.7 mM glucose in culture medium) was 117.0 ± 7.6 pg • islet" 1 • h~1 for free islets compared to 103.9 ± 23.9 pg • islet' 1 • h" 1 for encapsulated islets. Under high-glucose stimulation (20 mM glucose in culture medium) for 24 h, insulin secretion was elevated in both groups: 2651.1 ± 433.8 pg • islet" 1 • h" 1 for free islets and 1937.4 ± 411.7 pg • islet" 1 • h" 1 for encapsulated islets.
Intraperitoneal transplants of 4-5 x 10 3 encapsulated islets reversed the diabetic state of all 10 recipient BB rats. Mean ± SD fasting blood glucose levels dropped from a pretransplantation level of 22.0 ± 2.7 to 4.7 ± 1.3 mM within 3 days after transplantation, and normal blood glucose levels persisted for ~6 mo (Fig. 2) .
To determine whether the normoglycemic state of the transplant recipients resulted directly from the transplantation of microencapsulated islets, encapsulated islets were removed from one recipient 67 days after transplantation. The fasting blood glucose level in this rat increased from a normal postimplantation level to 21.2 mM within 2 days after the removal of the encapsulated islets. Approximately 90% of the implanted capsules were recovered. Of these, -70% were free floating and free of cell overgrowth. Viable islets were detected by dithizone (diphenylthiocarbazone) staining (Fig. 3) . The remaining 30% of the capsules had cells growing on their membranes. The rat died 22 days after the capsules were removed.
Two recipients each received a second transplant of -2.5-3.5 x 10 3 encapsulated islets after the reappearance of hyperglycemia at 76 and 92 days posttransplantation. Both recipients again became normoglycemic within 3 days of the second transplant and remained normoglycemic for 114 and 84 days, respectively.
Normal body weight was maintained in all transplant recipients during their normoglycemic period (Fig. 4) . Normal urine volume and the absence of any evidence of cataract development were also observed.
Transplants of unencapsulated islets reversed the hyperglycemia of the five control recipients within 3-4 days. However, in contrast to the experimental group, hyperglycemia returned after only 4-7 postoperative days in these rats (Fig.  5) . Only two recipients received insulin injections after the reappearance of hyperglycemia. These animals survived for 80 and 84 days, respectively.
DISCUSSION
The spontaneously diabetic BB rat was a valuable experimental model of human type I diabetes in this study. The course of development of the disease in this model resembles that of human type I diabetes in that there is an abrupt onset of insulin-dependent ketosis-prone diabetes and lymphocytic insulitis with virtually complete destruction of the pancreatic p-cells (4, 5) . Therefore, the autoimmune etiology of this animal allowed us to investigate the effectiveness of pancreatic islets in an immunoisolated environment. This study clearly demonstrated that transplantation of encapsulated islet allografts into diabetic BB rats reversed the diabetic state of these rats and maintained normoglycemia for up to 6 mo. In comparison, unencapsulated islet transplants maintained normoglycemia for no longer than 2 wk. The results demonstrate that both encapsulated and free islets were capable of secreting sufficient amounts of insulin to meet the physiological needs of the recipients and hence reverse the diabetic state. However, in contrast to free islets, the encapsulation procedure served to prolong the survival of the islets by protecting the p-cells from both graft rejection and autoimmune destruction. This protective capability of the alginate-polylysine-alginate membrane was demonstrated by Darquy and Reach (7) . In their in vitro study, rat islets encapsulated in this membrane were protected from the cytotoxic effects of anti-islet antibodies in the serum of individuals with newly diagnosed type I diabetes. Furthermore, in view of accumulating evidence that type I diabetes is an autoimmune disease, unprotected cells may well be susceptible to destruction by a recurrence of the autoimmune process. Therefore, encapsulation of islets appears to provide total protection from the host immune system while eliminating the need for immunosuppression.
In the course of this experiment, it was interesting to note that the preparation of perfect capsules is far from simple. The quality of the capsule varies from preparation to preparation and from person to person. Capsule strength plays an important role in in vivo studies. When the capsules are not strong, they tend to collapse a few days after transplantation. Viscosity of the alginate solution and alginate-polylysine reaction time must be strictly tested and controlled; otherwise, capsule strength and the smoothness of the capsular membrane will not be ideal, resulting in breakdown.
Because no biomaterial is 100% biocompatible, it is inevitable that some capsules will eventually attract cell overgrowth. We have noticed that many factors can promote overgrowth. Sphericity, the smoothness of the capsule surface, and the composition and sterility of the alginate each play an important role in the prevention of cell overgrowth. Of course, one of the most crucial steps in making good capsules is the outer coating of alginate. In the absence of this coating, polylysine tends to promote the attachment of fibroblasts. If the coating is not complete or the quality of the alginate is unsatisfactory, capsules tend to be completely covered by cell growth within 1 wk posttransplantation, and inflammatory reactions to the implanted capsules often occur (8) .
In conclusion, we demonstrated that encapsulation of pancreatic islets in an alginate-polylysine-alginate membrane significantly prolonged allograft survival in diabetic BB rats in the absence of immunosuppression therapy. Further studies are warranted to investigate the potential of microencapsulated islet transplants as a clinical treatment of type I diabetes.
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